Reference
Peptide dosage chart
A sortable at-a-glance table of reported dosing ranges, half-life, route and evidence grade for every compound in the database. Figures come from published studies and community protocols — they are not recommendations.
| Compound | Category | Common dosing | Half-life | Route | Evidence |
|---|---|---|---|---|---|
| BPC-157 Body Protection Compound 157 | Recovery & repair | 200–500 mcg | Approximately 4 hours (stable oral form debated) | Subcutaneous injection; oral capsules used for gut-specific goals | Emerging |
| TB-500 Thymosin Beta-4 fragment | Recovery & repair | 2–5 mg | Roughly 2–3 hours, with tissue effects lasting far longer | Subcutaneous or intramuscular injection | Emerging |
| CJC-1295 Modified GRF 1-29 | Growth hormone | 100 mcg | ~30 minutes without DAC; ~6–8 days with DAC | Subcutaneous injection, typically before bed on an empty stomach | Moderate |
| Ipamorelin NNC 26-0161 | Growth hormone | 200–300 mcg | About 2 hours | Subcutaneous injection, 1–3 times daily | Moderate |
| Tesamorelin Egrifta | Growth hormone | 2 mg | 26–38 minutes | Daily subcutaneous injection, abdomen | Strong |
| Semaglutide Ozempic | Metabolic | 0.25 mg | About 7 days | Once-weekly subcutaneous injection (oral tablet also approved) | Strong |
| Tirzepatide Mounjaro | Metabolic | 2.5 mg | About 5 days | Once-weekly subcutaneous injection | Strong |
| Retatrutide LY3437943 | Metabolic | 2 mg | About 5–7 days | Once-weekly subcutaneous injection | Strong |
| MOTS-c Mitochondrial open reading frame of the 12S rRNA-c | Metabolic | 5–10 mg | Estimated minutes to a few hours | Subcutaneous injection; oral capsules are marketed but less validated | Emerging |
| AOD-9604 Anti-Obesity Drug 9604 | Metabolic | 300 mcg | Under 30 minutes | Subcutaneous injection, often fasted in the morning | Limited |
| 5-Amino-1MQ 5-amino-1-methylquinolinium | Metabolic | 50–150 mg | Estimated several hours | Oral capsule | Limited |
| Epitalon Epithalon | Longevity | 5–10 mg | Minutes — effects attributed to gene expression rather than plasma level | Subcutaneous injection; intranasal versions exist | Limited |
| SS-31 Elamipretide | Longevity | ~40 mg | Roughly 2 hours | Daily subcutaneous injection | Moderate |
| NAD+ Nicotinamide adenine dinucleotide | Longevity | 250–750 mg | Very short in circulation | IV infusion, subcutaneous injection or nasal spray | Emerging |
| Semax ACTH(4-10) analogue | Cognitive | 300–600 mcg | Minutes intranasally; central effects persist for hours | Intranasal spray or drops | Limited |
| Selank Tuftsin analogue | Cognitive | 250–750 mcg | Short — dosed 1–3 times daily | Intranasal spray | Limited |
| GHK-Cu Copper peptide | Skin & hair | 1–3% serum | Not applicable topically; short systemically | Topical serum, microneedling adjunct or subcutaneous injection | Moderate |
| Melanotan II MT-2 | Skin & hair | 250–500 mcg | About 33 hours | Subcutaneous injection | Limited |
| PT-141 Bremelanotide | Sexual health | 1.75 mg | About 2.7 hours | Subcutaneous auto-injector, 45 minutes before activity | Strong |
| Kisspeptin-10 Metastin fragment 45-54 | Sexual health | Weight-based microgram doses | Under 30 minutes | Subcutaneous injection | Emerging |
Dosing figures describe ranges reported in the literature and community protocols. They are provided for educational comparison only and are not a recommendation for any individual.